Novo Nordisk reports semaglutide trial results in children with obesity

Key highlights
  • Nearly 80% of children on semaglutide had a BMI reduction of at least 10%, compared with 0% on placebo.
  • At week 68, estimated mean BMI change was −17.4% with semaglutide and +2.2% with placebo under the efficacy estimand.
  • At week 68, 83% of children on semaglutide improved their BMI category, compared with 23.5% on placebo.
  • STEP Young enrolled 167 children aged 6 to under 12; primary endpoint completion was in October 2025.

Trial results

Novo Nordisk reported results from the phase 3 STEP Young trial of once-weekly semaglutide in 167 children aged 6 to under 12 with obesity. Both trial groups also followed a reduced-calorie diet and increased physical activity. At week 68, estimated mean BMI change was −17.4% with semaglutide and +2.2% with placebo under the efficacy estimand. BMI category improved for 83% of children receiving semaglutide, versus 23.5% on placebo. The report also states that nearly 80% of children taking semaglutide had a BMI reduction of at least 10%, compared with none receiving placebo.

Safety and status

The overall safety and tolerability profile was consistent with previous pediatric and adult semaglutide trials, with no unexpected safety concerns or concerns identified for growth or pubertal development. Semaglutide injection is investigational for children under 12 in the United States; its safety and efficacy in this age group have not been established.

Trial timeline

The trial began in July 2023. Primary endpoint completion at week 68 was in October 2025, end-of-treatment completion at week 104 was in May 2026, and the week 111 off-drug safety follow-up was completed in July 2026.

Source: Novo Nordisk

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time. See our Privacy Policy.